Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -1.77% and Operating profit at 13.75% over the last 5 years
2
Flat results in Mar 25
3
With ROE of 0.17%, it has a expensive valuation with a 3.84 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 27,634 Million (Large Cap)
2,252.00
NA
0.00%
-0.11
0.17%
3.84
Revenue and Profits:
Net Sales:
1,267 Million
(Quarterly Results - Jun 2025)
Net Profit:
9 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.72%
0%
-8.72%
6 Months
-26.3%
0%
-26.3%
1 Year
5.85%
0%
5.85%
2 Years
-9.13%
0%
-9.13%
3 Years
-20.72%
0%
-20.72%
4 Years
-32.54%
0%
-32.54%
5 Years
-24.91%
0%
-24.91%
Kangmei Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.77%
EBIT Growth (5y)
13.75%
EBIT to Interest (avg)
-12.02
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
0.65
Tax Ratio
66.98%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.12%
ROE (avg)
17.90%
Valuation key factors
Factor
Value
P/E Ratio
2252
Industry P/E
Price to Book Value
3.84
EV to EBIT
-71.36
EV to EBITDA
-1631.87
EV to Capital Employed
4.20
EV to Sales
5.14
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-5.89%
ROE (Latest)
0.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,266.90
1,287.50
-1.60%
Operating Profit (PBDIT) excl Other Income
86.80
86.30
0.58%
Interest
1.50
1.70
-11.76%
Exceptional Items
0.00
-0.00
Consolidate Net Profit
9.30
9.00
3.33%
Operating Profit Margin (Excl OI)
2.90%
2.40%
0.05%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -1.60% vs 0.41% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 3.33% vs 125.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5,121.50
5,148.20
-0.52%
Operating Profit (PBDIT) excl Other Income
-52.60
474.80
-111.08%
Interest
22.40
57.90
-61.31%
Exceptional Items
320.60
-89.10
459.82%
Consolidate Net Profit
12.10
103.60
-88.32%
Operating Profit Margin (Excl OI)
-83.20%
20.60%
-10.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -0.52% vs 29.19% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -88.32% vs 103.85% in Dec 2023
About Kangmei Pharmaceutical Co., Ltd. 
Kangmei Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






